Moser Wealth Advisors LLC Cuts Stake in The Clorox Company $CLX

Moser Wealth Advisors LLC lowered its position in shares of The Clorox Company (NYSE:CLX) by 8.2% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,575 shares of the company’s stock after selling 320 shares during the period. Moser Wealth Advisors LLC’s holdings in Clorox were worth $429,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Clorox by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 15,573,076 shares of the company’s stock valued at $2,293,135,000 after buying an additional 65,924 shares during the period. Northern Trust Corp increased its stake in shares of Clorox by 2.3% in the 1st quarter. Northern Trust Corp now owns 1,528,920 shares of the company’s stock worth $225,133,000 after acquiring an additional 34,655 shares in the last quarter. Invesco Ltd. increased its stake in shares of Clorox by 7.4% in the 1st quarter. Invesco Ltd. now owns 1,361,710 shares of the company’s stock worth $200,512,000 after acquiring an additional 94,371 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Clorox by 3.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,157,257 shares of the company’s stock worth $170,406,000 after acquiring an additional 41,485 shares in the last quarter. Finally, Hsbc Holdings PLC increased its stake in shares of Clorox by 118.8% in the 1st quarter. Hsbc Holdings PLC now owns 1,085,661 shares of the company’s stock worth $159,699,000 after acquiring an additional 589,544 shares in the last quarter. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Clorox Stock Performance

CLX opened at $116.37 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.57 and a debt-to-equity ratio of 5.15. The company has a market cap of $14.17 billion, a price-to-earnings ratio of 17.85, a PEG ratio of 0.98 and a beta of 0.52. The company’s 50 day moving average is $121.30 and its 200 day moving average is $127.15. The Clorox Company has a 12-month low of $116.32 and a 12-month high of $171.37.

Clorox (NYSE:CLX) last posted its quarterly earnings data on Thursday, July 31st. The company reported $2.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.24 by $0.63. The company had revenue of $1.99 billion for the quarter, compared to the consensus estimate of $1.94 billion. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The firm’s revenue was up 4.5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.82 earnings per share. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. On average, equities research analysts predict that The Clorox Company will post 7.15 EPS for the current year.

Clorox Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, November 6th. Shareholders of record on Wednesday, October 22nd will be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Wednesday, October 22nd. This represents a $4.96 annualized dividend and a yield of 4.3%. Clorox’s payout ratio is currently 76.07%.

Insiders Place Their Bets

In other Clorox news, COO Eric H. Reynolds sold 15,041 shares of Clorox stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the transaction, the chief operating officer owned 54,221 shares of the company’s stock, valued at $6,711,475.38. The trade was a 21.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.63% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

CLX has been the subject of several research reports. JPMorgan Chase & Co. decreased their price target on shares of Clorox from $135.00 to $127.00 and set a “neutral” rating for the company in a research note on Friday, October 10th. UBS Group reduced their price objective on shares of Clorox from $134.00 to $128.00 and set a “neutral” rating for the company in a research note on Wednesday, October 8th. TD Cowen reduced their price objective on shares of Clorox from $120.00 to $117.00 and set a “hold” rating for the company in a research note on Wednesday, October 1st. Zacks Research upgraded shares of Clorox from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Finally, Citigroup reduced their price objective on shares of Clorox from $135.00 to $130.00 and set a “neutral” rating for the company in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, twelve have assigned a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $130.20.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.